TGF-β Receptor 2 (TGFBR2) is a transmembrane serine/threonine kinase that serves as the primary type II receptor for transforming growth factor-beta ligands in the nervous system. This protein plays critical roles in initiating TGF-β signaling that regulates neuroinflammation, neuronal survival, synaptic plasticity, and glial function.
TGF-β Receptor 2 (TGFBR2) is a transmembrane serine/threonine kinase that serves as the primary type II receptor for transforming growth factor-beta ligands in the nervous system. This protein plays critical roles in initiating TGF-β signaling that regulates neuroinflammation, neuronal survival, synaptic plasticity, and glial function.
Overview
TGFBR2 (Transforming Growth Factor Beta Receptor 2) is a 70 kDa transmembrane receptor kinase that initiates TGF-β signaling by binding TGF-β ligands and phosphorylating type I receptors (TGFBR1)[@massague2000]. As the primary type II receptor, TGFBR2 is constitutively active and essential for all downstream TGF-β signaling in the nervous system[@heldin2021].
The study of Tgf Β Receptor 2 (Tgfbr2) Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
Massague J, TGF-beta signal transduction (2000)
Heldin CH, et al, TGF-beta signaling mechanisms (2021)
Brionne TC, et al, Loss of TGF-beta signaling in neurons (2021)
Kane CJ, et al, TGF-beta neuroprotection in PD models (2018)
Ferguson L, et al, TGF-beta and synaptic plasticity (2019)
Tichauer JE, et al, TGF-beta and BBB (2020)
Palazuelos J, et al, TGFBR2 and oligodendrocyte differentiation (2021)
Caraci F, et al, TGF-beta alterations in AD (2021)
Wyss-Coray T, et al, TGF-beta and neuroinflammation (2020)
Mousseau M, et al, TGFBR2 variants and AD risk (2021)
Rai SN, et al, TGF-beta protection in dopaminergic neurons (2022)
Reynolds CH, et al, TGF-beta and alpha-synuclein (2021)
Tong J, et al, TGFBR2 in PD (2019)
Dormann D, et al, TGF-beta in ALS (2020)
Ilieva H, et al, TGF-beta pathway in ALS (2019)
Palazuelos J, et al, TGFBR2 in OPC function (2021)
McQueen J, et al, TGF-beta in MS (2020)
Zhang B, et al, LY2109761 in cancer therapy (2019)
Inman GJ, et al, SB-431542 is a potent inhibitor of TGF-beta signaling (2002)
Sakauchi M, et al, TGF-beta agonists for neuroprotection (2021)
Akhurst RJ, et al, TGFBR2 agonists in disease (2021)